4DMedical stock

4DX · ASX · AUD

Compare 4DMedical
$2.16Change from previous close: −4.42%Absolute change: −$0.10

Close · November 20, 2026

Price history

+48.45% over the period

1 year: from $1.46 (November 20, 2025) to $2.16 (November 20, 2026), +48.45%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026$2.16
October 30, 2026$2.44
September 30, 2026$4.25
August 31, 2026$3.42
July 31, 2026$3.63
June 30, 2026$4.53
May 29, 2026$3.97
April 30, 2026$4.01
March 31, 2026$5.56
February 27, 2026$4.00
January 30, 2026$3.17
December 31, 2025$3.93
November 28, 2025$1.71
November 20, 2025$1.46

At a glance

  • The company

    Develop non-invasive respiratory imaging software and solutions for lung health assessment and drug development

  • Latest results

    Quarter to June 30, 2026 · EPS -$0.07 (estimate -$0.03)

TickerLandia's take on 4DMedical

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$1.44
52-wk high$7.55

−71.39% from the 52-week high

Analysts · 3 analysts

Average target$4.17+92.90% vs. price

Buy 1 · Hold 2 · Sell 0

TickerLandia Fingerprint: 4DMedical

Compared with similar companies: very low earnings stability, very high growth, and very high risk.

Financials and price compared with 44 companies in related industries (health_services), worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

4DMedical is pricier than similar companies

4DMedical's Price/book: 7.58, +31% against the median of a group of 7 similar companies (5.80).

Compared with 7 similar companies

4DMedical's metrics compared with similar companies
Metric4DMedicalPosition in the groupBand
Operating margin-813.7%Low
ROE-174.4%Low
Debt/equity1.06High
Price/book7.58Middle
Net margin0.0%Middle

Grey band: the middle half of the group; tick: the median; dot: 4DMedical. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$4.21M

Latest quarter · Q2 2026

Net income

-$50.3M

Latest quarter · Q2 2026

Quarterly net margin

-1,194.8%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$1.3B
EPS
-$0.38
Volume
4.32M
Daily trading
€9.69M
Dividend yield
0.00%

How 4DMedical is changing

All results
  • Revenue grew 100.7% a year on average over the last 5 years

  • Operating margin rose from −6,202.5% to −813.7%

  • Shares outstanding up 109.8% in 5 years

Returns

4DMedical returns

$1,000 invested in 4DMedical 5 years ago, on November 22, 2021, would be worth $1,800 today: +80.00% in total, +12.49% per year. This is the price return only: dividends are excluded.

Period4DMedicalS&P/ASX 200$1,000 becomes
1 month−42.09%−2.54%$579
6 months−34.15%+1.13%$659
Year to date−45.04%−1.40%$550
1 year+48.45%+0.47%$1,485
3 years+204.23%+21.74%$3,042
5 years+80.00%+16.86%$1,800

Over the last 6 months it has done better than 25% of the stocks in the Technology sector.

Price only, without dividends. Calculate your investment

The chart in detail

4DMedical: technical analysis

4DMedical is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 68.2% below its all-time closing high ($6.80, April 10, 2026).

Trend
Downward
RSI (14 sessions)
31
Between 30 and 70
vs 200-session average
−45.65%

Support and resistance

Price areas where 4DMedical has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$3.64+68.29%4 touches, last on October 15, 2026
  2. Resistance$3.29+52.24%3 touches, last on September 11, 2026
  3. Resistance$3.03+40.43%3 touches, last on July 24, 2026
  4. Last price$2.16
  5. No support below: the price is near the lows of the year

Volatility and risk

Over the last year it has moved more than the S&P/ASX 200.

Beta (1 year) vs S&P/ASX 200
2.37
Volatility (60 sessions, annualised)
94.9%
Largest fall in the last year
−68.68%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

4DMedical: seasonality

Average monthly price change over 7 years

−8.1%Jan−9.4%Feb+1.5%Mar+21.1%Apr−6.1%May−8.8%Jun+3.6%Jul+20.0%Aug+40.5%Sep−4.8%Oct+10.9%Nov+16.8%Dec

Over the last 7 years, the strongest month for 4DMedical has been September: +40.55% on average, positive in 4 years out of 7. The weakest has been February: −9.40% on average, positive in 2 years out of 6. November, the current month, has been positive in 2 years out of 6 (+10.92% on average).

Show chart data
MonthAverageMedianPositive years
January−8.07%−13.82%2 of 6
February−9.40%−15.28%2 of 6
March+1.46%−1.42%2 of 6
April+21.05%−7.92%2 of 6
May−6.08%−5.54%1 of 6
June−8.83%−10.20%1 of 6
July+3.58%+1.49%3 of 6
August+19.97%−3.56%2 of 6
September+40.55%+14.48%4 of 7
October−4.75%−7.51%3 of 7
November+10.92%−1.08%2 of 6
December+16.79%+1.44%3 of 6

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

4DMedical and its competitors

Pharmaceutical developers, clinical researchers and lung-health programmes in the United States and Australia are the core of the market served by 4DMedical Limited, a medical technology company that develops non-invasive respiratory imaging. Its range includes CT:VQ, a non-contrast post-processing technology, CAC for non-contrast cardiothoracic risk assessment, LDAi for automated detection of potential emphysema, and the XV Scanner, a lung function scanner. Its XV LVAS and CT LVAS software image lung airflow and regional lung function.

Headquarters
Carlton, Australia
Employees
181
Founded
2012
Chief executive
Andreas Fouras
4DMedical and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
4DMedical4DX$867.27M-813.7%—−34.15%
XtalPi Holdings2228$3B-124.6%—−39.24%
M32413$7.04B19.5%24.4+19.18%
Pro MedicusPME$13.08B74.9%76.0+45.89%
DoximityDOCS$5.13B27.1%39.9+44.66%
Tempus AITEM$9.86B-18.5%—+17.79%

Same industry or related industries, similar size. Compare 4DMedical with its competitors · Full profile